Last reviewed · How we verify
Human-Spongiosa
Human-Spongiosa is a Small molecule drug developed by University Medicine Greifswald. It is currently FDA-approved. Also known as: Knochenspongiosa of human origin.
Human-Spongiosa is a protein that acts as a bilirubin sequestering agent, classified as a SEQUESTERING AGENT. It is being studied in clinical trials for conditions such as missing teeth, alveolar bone loss, and bone resorption, often in conjunction with interventions like autogenous bone grafts or augmentation surgery.
At a glance
| Generic name | Human-Spongiosa |
|---|---|
| Also known as | Knochenspongiosa of human origin |
| Sponsor | University Medicine Greifswald |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alveolar Management Following Teeth Extraction (PHASE4)
- Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human-Spongiosa CI brief — competitive landscape report
- Human-Spongiosa updates RSS · CI watch RSS
- University Medicine Greifswald portfolio CI
Frequently asked questions about Human-Spongiosa
What is Human-Spongiosa?
Who makes Human-Spongiosa?
Is Human-Spongiosa also known as anything else?
What development phase is Human-Spongiosa in?
Related
- Manufacturer: University Medicine Greifswald — full pipeline
- Also known as: Knochenspongiosa of human origin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing